Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme.

Gruslova A, Cavazos DA, Miller JR, Breitbart E, Cohen YC, Bangio L, Yakov N, Soundararajan A, Floyd JR, Brenner AJ.

J Neurooncol. 2015 Sep;124(3):365-72. doi: 10.1007/s11060-015-1853-7. Epub 2015 Jun 25.


Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.

Brenner AJ, Cohen YC, Breitbart E, Bangio L, Sarantopoulos J, Giles FJ, Borden EC, Harats D, Triozzi PL.

Clin Cancer Res. 2013 Jul 15;19(14):3996-4007. doi: 10.1158/1078-0432.CCR-12-2079. Epub 2013 Apr 15.


Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.

Reddi HV, Madde P, Cohen YC, Bangio L, Breitbart E, Harats D, Bible KC, Eberhardt NL.

Genes Cancer. 2011 Oct;2(10):993-5. doi: 10.1177/1947601912437933.


Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK.

Hodish I, Tal R, Shaish A, Varda-Bloom N, Greenberger S, Rauchwerger A, Breitbart E, Bangio L, Ben-Shushan D, Pfeffer R, Feder B, Waitsman A, Barshack I, Goldberg I, Mazaki-Tovi S, Peled M, Harats D.

Cancer Biol Ther. 2009 Mar;8(5):424-32. Epub 2009 Mar 19.


Systemic administration of a conditionally replicating adenovirus, targeted to angiogenesis, reduced lung metastases burden in cotton rats.

Peled M, Shaish A, Katav A, Greenberger S, Barshack I, Tal R, Bangio L, Breitbart E, Harats D.

Clin Cancer Res. 2009 Mar 1;15(5):1664-73. doi: 10.1158/1078-0432.CCR-08-1670. Epub 2009 Feb 24.


Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.

Varda-Bloom N, Hodish I, Shaish A, Greenberger S, Tal R, Feder B, Roitelman J, Breitbart E, Bangio L, Barshack I, Pfeffer R, Harats D.

Pathobiology. 2008;75(6):346-55. doi: 10.1159/000164219. Epub 2008 Dec 15.


Endothelial-targeted Gene Transfer of Hypoxia-inducible Factor-1α Augments Ischemic Neovascularization Following Systemic Administration.

Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A, Barshack I, Bangio L, Hodish I, Greenberger S, Peled M, Breitbart E, Harats D.

Mol Ther. 2008 Dec;16(12):1927-1936. doi: 10.1038/mt.2008.191. Epub 2016 Dec 8.


Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration.

Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A, Barshack I, Bangio L, Hodish I, Greenberger S, Peled M, Breitbart E, Harats D.

Mol Ther. 2008 Dec;16(12):1927-36. doi: 10.1038/mt.2008.191. Epub 2008 Sep 16.


Activation of C-transactivation domain is essential for optimal HIF-1 alpha-mediated transcriptional and angiogenic effects.

Tal R, Shaish A, Bangio L, Peled M, Breitbart E, Harats D.

Microvasc Res. 2008 May;76(1):1-6. doi: 10.1016/j.mvr.2008.03.002. Epub 2008 Mar 20.


Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect.

Peled M, Shaish A, Greenberger S, Katav A, Hodish I, Ben-Shushan D, Barshack I, Mendel I, Frishman L, Tal R, Bangio L, Breitbart E, Harats D.

Cancer Gene Ther. 2008 Aug;15(8):535-42. doi: 10.1038/cgt.2008.20. Epub 2008 Apr 18.


Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I.

George J, Yacov N, Breitbart E, Bangio L, Shaish A, Gilburd B, Shoenfeld Y, Harats D.

Cardiovasc Res. 2004 Jun 1;62(3):603-9.


Transcription-controlled gene therapy against tumor angiogenesis.

Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I, Barshack I, Hodish I, Yaacov N, Bangio L, Goncharov T, Wallach D, Harats D.

J Clin Invest. 2004 Apr;113(7):1017-24.

Supplemental Content

Loading ...
Support Center